Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab

Combined treatment with bevacizumab and trifluridine/tipiracil (TAS-102) leads to an increased chance of survival in patients with refractory metastatic colorectal cancer (mCRC); however, this treatment is associated with an increased frequency of severe neutropenia (number of neutrophils <1,000)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaki, Sawako, Ishikawa, Hideki, Suzuki, Koichi, Kimura, Yasuaki, Maemoto, Ryo, Abe, Iku, Endo, Yuhei, Kakizawa, Nao, Watanabe, Fumiaki, Futsuhara, Kazushige, Saito, Masaaki, Tsujinaka, Shingo, Miyakura, Yasuyuki, Rikiyama, Toshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022083/
https://www.ncbi.nlm.nih.gov/pubmed/35463210
http://dx.doi.org/10.3892/mco.2022.2536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022083/
https://www.ncbi.nlm.nih.gov/pubmed/35463210
http://dx.doi.org/10.3892/mco.2022.2536

Ejemplares similares